REACHing Communities (REACH) Consortium (U01) Clinical Trials Optional
🏛 Food and Drug Administration (HHS-FDA)
✓ Free, no account · Source: Grants.gov · Last verified Jul 15, 2026
Can you apply?
This grant is for clinical research organizations conducting FDA-regulated medical product studies. Eligible applicants include academic medical centers, hospitals, community health centers, and research institutions with IRB approval capabilities. Geographically, applicants must focus on recruiting underrepresented populations in clinical trials. The program supports multicenter clinical trial networks that expand access to research participation in underserved communities.
Not the right fit? Find grants for your organization in 5 questions →
Program description
This purpose of this notice of funding opportunity (NOFO) is for FDA Office of Minority Health and Health Equity’s (OMHHE) Health Equity Innovation Award: Racial & Ethnic Minority Acceleration Consortium for Health Equity (REACH). The consortium will consist of multiple cooperative agreement (U01) recipients that will strengthen and advance minority health and health equity focused research, outreach, and communications as well as support training and mentoring of diverse students, fellows, and/or researchers.
Who can apply
Eligible applicants
- 501(c)(3) Public Charity
- City / Municipal Government
- Community Health Center
- County Government
- Hospital
- Nonprofits
- Private University
- Public Authority
- Public K-12 School
- Public University
- Small Business (SBA-defined)
- Special District
- State Government
- Tribal Nation
- Tribal Organization
Demographic focus
How to apply
Application links
Required documents
- SF-424 and SF-424(R&R)
- Project Narrative
- Budget and Budget Justification
- Institutional IRB approval or commitment letter
- Letters of collaboration from community partners
- Biosketches of key personnel
- Facilities and equipment description
Program contact
- 👤 Terrin Brown Grantor
- 📧 terrin.brown@fda.hhs.gov
- 📞 2404027610
Funding track record
Recent awards under CFDA 93.103 from the last 3 years — real organizations that won funding through this same program.
Top 10 Largest Recent Awards
-
$121,795,918
-
$76,105,626
-
$50,217,964
-
$47,940,304
-
$36,000,000
-
$35,573,997
-
$35,391,995
-
$30,732,300
-
$23,332,999
-
$21,347,288
Top States by Funding
- AZ 3 awards $131.4M
- MD 7 awards $108.7M
- CA 9 awards $106.5M
- VA 5 awards $96.6M
- PA 10 awards $77.4M
Source: USAspending.gov — federal spending transparency. Data covers last 3 years.
Funding history
Annual funding for this program — Federal obligations (CFDA 93.103). How funding has trended year over year.
| 2016 | $170,482,435 | |
| 2017 est. | $208,900,832 | |
| 2018 | $173,077,408 | |
| 2019 | $198,507,896 | |
| 2020 | $212,448,590 | |
| 2021 | $218,918,739 | |
| 2022 est. | $255,910,458 | |
| 2023 est. | $246,894,600 |
FAQ
Who can apply for the REACH Consortium grant?
Academic medical centers, hospitals, research universities, and community-based clinical research organizations. All applicants need institutional IRB capacity.
What types of studies does REACH support?
FDA-regulated clinical trials with focus on recruiting underrepresented and historically excluded populations. Studies in any therapeutic area are eligible.
How much funding is typically available?
U01 grants from FDA typically range from $300K-$500K annually. Consult the FOA for specific budget caps.
What makes an application competitive?
Strong partnerships with underserved communities, clear recruitment strategies for diverse populations, and established institutional research infrastructure.
When is the deadline?
Check grants.gov for current deadline dates, as they vary by funding cycle.
💡 Tips for applicants
- Build partnerships with community organizations to demonstrate genuine commitment to enrolling underrepresented participants. This is the core requirement.
- Document your institution's existing capacity: IRB approval, clinical trial infrastructure, and past recruitment success with diverse populations.
- Clearly define which FDA-regulated products your trials will study and explain why diverse participation is scientifically important.
- Include a realistic recruitment timeline with specific metrics for enrolling underrepresented populations.
- Engage community advisory boards early. Show how their feedback shaped your study design and recruitment approach.
⚠️ Common mistakes
Underestimating the importance of community partnerships—reviewers fund true collaborations, not token engagement. Failing to explain why diverse populations are underrepresented in your specific research area. Submitting a generic clinical trial proposal without centering health equity and underserved communities.
Similar grants
- ROLLING Health Equity Innovation Award: Enhance Equity Funding Opportunity (U01) Clinical Trials Not Allowed — Food and Drug Administration
- CLOSED FDA OMHHE Convener for Racial & Ethnic minority Acceleration Consortium for Health Equity (REACH) — Food and Drug Administration
- OPEN Clinical and Translational Science Award (UM1 Clinical Trial Optional) — National Institutes of Health
- OPEN Leveraging Network Infrastructure to Conduct Innovative Research for Women, Children, Pregnant and Lactating Women, and Persons with Disabilities (UG3/UH3 – Clinical Trial Optional) — National Institutes of Health
- CLOSED Notice of Intent to Publish a Forecast for EmbraceHealth Clinical Research Network to Reduce Health Disparities – Research Sites — National Institutes of Health